Press Release
For Immediate Distribution

glenmark
A new way for a new world

Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package

Elmwood Park, New Jersey, August 21, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch[1] of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark's Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].

According to IQVIA® sales data for the 12-month period ending June 2026, the Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL) market[2] achieved annual sales of approximately $69.9 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark's U.S. injectables business and expanding our hospital portfolio.

It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business – one that addresses institutional needs, supports greater supply resilience and deepens Glenmark's relevance across the U.S. healthcare system," **he added.**

[1]Glenmark's Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package is only approved for the indication(s) listed in Glenmark's approved label.

[2]Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for and will only be marketed for the indications listed in Glenmark's approved label, which may be different than the approved RLD indications.

*IQVIA® National Sales Perspectives: Retail & Non-Retail, June 2026

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact:

India	United States
Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999 Adfactors PR glenmark.ihcp@adfactorspr.com +91 9535635461	Akhila Natarajan mediarelations@glenmarkpharma.com Danielle Hagen danielle@nahigianstrategies.com 202-365-6112